Vesicoureteral reflux

Current trends in diagnosis, screening, and treatment

Jonathan C. Routh, Guy A. Bogaert, Martin Kaefer, Gianantonio Manzoni, John M. Park, Alan B. Retik, H. Gil Rushton, Warren T. Snodgrass, Duncan T. Wilcox

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Context: Vesicoureteral reflux (VUR) is present in approximately 1% of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. Objective: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. Evidence acquisition: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. Evidence synthesis: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. Conclusions: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments.

Original languageEnglish
Pages (from-to)773-782
Number of pages10
JournalEuropean Urology
Volume61
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Vesico-Ureteral Reflux
Therapeutics
Morbidity
Kidney
Pyelonephritis
North America
Cicatrix
Medicine
Organizations
Databases
Guidelines

Keywords

  • Diagnosis
  • Pediatrics
  • Screening
  • Treatment
  • Vesicoureteral reflux

ASJC Scopus subject areas

  • Urology

Cite this

Routh, J. C., Bogaert, G. A., Kaefer, M., Manzoni, G., Park, J. M., Retik, A. B., ... Wilcox, D. T. (2012). Vesicoureteral reflux: Current trends in diagnosis, screening, and treatment. European Urology, 61(4), 773-782. https://doi.org/10.1016/j.eururo.2012.01.002

Vesicoureteral reflux : Current trends in diagnosis, screening, and treatment. / Routh, Jonathan C.; Bogaert, Guy A.; Kaefer, Martin; Manzoni, Gianantonio; Park, John M.; Retik, Alan B.; Rushton, H. Gil; Snodgrass, Warren T.; Wilcox, Duncan T.

In: European Urology, Vol. 61, No. 4, 04.2012, p. 773-782.

Research output: Contribution to journalArticle

Routh, JC, Bogaert, GA, Kaefer, M, Manzoni, G, Park, JM, Retik, AB, Rushton, HG, Snodgrass, WT & Wilcox, DT 2012, 'Vesicoureteral reflux: Current trends in diagnosis, screening, and treatment', European Urology, vol. 61, no. 4, pp. 773-782. https://doi.org/10.1016/j.eururo.2012.01.002
Routh, Jonathan C. ; Bogaert, Guy A. ; Kaefer, Martin ; Manzoni, Gianantonio ; Park, John M. ; Retik, Alan B. ; Rushton, H. Gil ; Snodgrass, Warren T. ; Wilcox, Duncan T. / Vesicoureteral reflux : Current trends in diagnosis, screening, and treatment. In: European Urology. 2012 ; Vol. 61, No. 4. pp. 773-782.
@article{9bf7c7d4b6fc4bb184cc51d054f75c9c,
title = "Vesicoureteral reflux: Current trends in diagnosis, screening, and treatment",
abstract = "Context: Vesicoureteral reflux (VUR) is present in approximately 1{\%} of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. Objective: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. Evidence acquisition: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. Evidence synthesis: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. Conclusions: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments.",
keywords = "Diagnosis, Pediatrics, Screening, Treatment, Vesicoureteral reflux",
author = "Routh, {Jonathan C.} and Bogaert, {Guy A.} and Martin Kaefer and Gianantonio Manzoni and Park, {John M.} and Retik, {Alan B.} and Rushton, {H. Gil} and Snodgrass, {Warren T.} and Wilcox, {Duncan T.}",
year = "2012",
month = "4",
doi = "10.1016/j.eururo.2012.01.002",
language = "English",
volume = "61",
pages = "773--782",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Vesicoureteral reflux

T2 - Current trends in diagnosis, screening, and treatment

AU - Routh, Jonathan C.

AU - Bogaert, Guy A.

AU - Kaefer, Martin

AU - Manzoni, Gianantonio

AU - Park, John M.

AU - Retik, Alan B.

AU - Rushton, H. Gil

AU - Snodgrass, Warren T.

AU - Wilcox, Duncan T.

PY - 2012/4

Y1 - 2012/4

N2 - Context: Vesicoureteral reflux (VUR) is present in approximately 1% of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. Objective: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. Evidence acquisition: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. Evidence synthesis: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. Conclusions: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments.

AB - Context: Vesicoureteral reflux (VUR) is present in approximately 1% of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. Objective: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. Evidence acquisition: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. Evidence synthesis: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. Conclusions: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments.

KW - Diagnosis

KW - Pediatrics

KW - Screening

KW - Treatment

KW - Vesicoureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=84862823799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862823799&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.01.002

DO - 10.1016/j.eururo.2012.01.002

M3 - Article

VL - 61

SP - 773

EP - 782

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -